You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Endoscopic Balloon Dilatation of Crohn's Disease Strictures: Results from a Large United Kingdom Series

Bhalme, Mahesh MRCP*; Sarkar, Sanchoy FRCP, PhD; Lal, Simon FRCP, PhD; Bodger, Keith FRCP, MD§,‖; Baker, Rose PhD, FRSS, FIMA, CStat, CMath; Willert, Robert P. FRCP, PhD**

Inflammatory Bowel Diseases:
doi: 10.1097/01.MIB.0000439067.76964.53
Original Clinical Articles

Introduction: Stricturing is a common complication of Crohn's disease. Endoscopic balloon dilatation (EBD) offers a valuable alternative to surgical intervention, but there are limited data on factors influencing its safety and efficacy.

Methods: A multicenter retrospective audit across 4 U.K. teaching hospitals was performed on the use of EBD for Crohn's strictures between 1998 and 2011. Demographics, smoking status, medications, C-reactive protein, endoscopic findings, and subsequent surgery at follow-up were recorded. Success of EBD was defined as symptomatic improvement without the need for surgery at follow-up.

Results: Seventy-nine patients (47 women; median age, 48 yr) were identified for this study. Forty-eight (61%) patients had ileocolonic anastomotic strictures, whereas the rest had de novo strictures. In total, 191 EBDs (range, 1–11; median 2) were carried out on 93 strictures (range, 1–5; median 1) over a median duration of 12 months (range, 1–84). There were no serious adverse events. Success at index EBD was 34%, with a further 43% achieving long-term benefit from additional EBDs. Eighteen (23%) patients required surgery. Time to surgery after the first EDB was 2.6 to 71.1 months (median, 12.8 mo). Longer Crohn's disease duration (P = 0.03) and high C-reactive protein (P = 0.008) were associated with an increased need for subsequent surgery.

Conclusions: EBD was safe and effective in achieving long-term symptom improvement and avoidance of surgery in most patients. Prospective controlled trials are needed to evaluate the effect of other factors, including Crohn's disease phenotype, and the role of concomitant medication to identify those best suited to EBD.

In Brief

Article first published online 26 December 2013

Author Information

*Royal Bolton Hospital, Bolton, United Kingdom;

Department of Gastroenterology and Hepatology, Royal Liverpool University Hospitals, Liverpool, United Kingdom;

Intestinal Failure Unit, Salford Royal Foundation Trust, Salford, United Kingdom;

§Department of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom;

Digestive Diseases Centre, Clinical Sciences Centre, Aintree University Hospital, Liverpool, United Kingdom;

School of Business, Salford University, Salford, United Kingdom; and

**Manchester Royal Infirmary, Central Manchester University Hospitals NHS Trust, Manchester, United Kingdom.

Reprints: Robert P. Willert, FRCP, PhD, Manchester Royal Infirmary, Central Manchester University Hospitals NHS Trust, Manchester M13 9WL, United Kingdom (e-mail:

Presented as part of CERT-N (Collaboration of Endoscopy Research and Training in Northwest England).

The authors have no conflicts of interest to disclose.

Received October 07, 2013

Accepted November 14, 2013

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.